Arcturus Therapeutics (ARCT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.34, -8.25% vs the prior close of $11.27.
- Volume 831.61K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ARCT slides 8.3% to $10.34, a 1-month low. Closed at $10.34, -8.25% vs the prior close of $11.27. Day range $10.25–$11.31, opened at $11.27.
ARCT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ARCT slides 8.3% to $10.34, a 1-month low
- Closed at $10.34, -8.25% vs the prior close of $11.27. Day range $10.25–$11.31, opened at $11.27.
- Volume was 831.61K shares, 0.8x its 50-day average of 1.08M.
- Price is -21.0% vs its 50-day average ($13.09) and +17.5% vs its 200-day average ($8.80).
- 52-week range $5.50–$24.17; today's close sits at 26% of that range, 57.2% below the 52-week high.
Oct 15, 2026 — ARCT rises 1.3% to $11.27
- Closed at $11.27, +1.35% vs the prior close of $11.12. Day range $10.61–$11.42, opened at $11.00.
- Volume was 492.90K shares, 0.5x its 50-day average of 1.08M — lighter than usual.
- Price is -13.3% vs its 50-day average ($13.00) and +28.4% vs its 200-day average ($8.78).
- 52-week range $5.50–$24.17; today's close sits at 31% of that range, 53.4% below the 52-week high.
Oct 14, 2026 — ARCT slides 7.6% to $11.12, a 1-month low, 3 down days in a row
- Closed at $11.12, -7.56% vs the prior close of $12.03. Day range $11.06–$12.05, opened at $11.64.
- Volume was 588.80K shares, 0.5x its 50-day average of 1.08M — lighter than usual.
- Price is -13.8% vs its 50-day average ($12.90) and +27.1% vs its 200-day average ($8.75).
- 52-week range $5.50–$24.17; today's close sits at 30% of that range, 54.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ARCT slides 4.6% to $12.03, a 1-month low
- Closed at $12.03, -4.60% vs the prior close of $12.61. Day range $11.86–$12.65, opened at $12.42.
- Volume was 464.10K shares, 0.4x its 50-day average of 1.08M — lighter than usual.
- Price is -6.1% vs its 50-day average ($12.81) and +37.9% vs its 200-day average ($8.73).
- 52-week range $5.50–$24.17; today's close sits at 35% of that range, 50.2% below the 52-week high.
Oct 12, 2026 — ARCT slides 8.2% to $12.61, a 1-month low
- Closed at $12.61, -8.22% vs the prior close of $13.74. Day range $12.57–$13.75, opened at $13.64.
- Volume was 419.40K shares, 0.4x its 50-day average of 1.07M — lighter than usual.
- Price is -0.6% vs its 50-day average ($12.68) and +45.0% vs its 200-day average ($8.70).
- 52-week range $5.50–$24.17; today's close sits at 38% of that range, 47.8% below the 52-week high.
Oct 9, 2026 — ARCT jumps 6.8% to $13.74
- Closed at $13.74, +6.76% vs the prior close of $12.87. Day range $12.87–$14.32, opened at $13.18.
- Volume was 675.60K shares, 0.6x its 50-day average of 1.07M.
- Price is +9.5% vs its 50-day average ($12.55) and +58.5% vs its 200-day average ($8.67).
- 52-week range $5.50–$24.17; today's close sits at 44% of that range, 43.2% below the 52-week high.
Oct 8, 2026 — ARCT rises 0.8% to $12.87
- Closed at $12.87, +0.78% vs the prior close of $12.77. Day range $12.03–$12.96, opened at $12.60.
- Volume was 677.80K shares, 0.6x its 50-day average of 1.06M.
- Price is +3.9% vs its 50-day average ($12.39) and +49.1% vs its 200-day average ($8.63).
- 52-week range $5.50–$24.17; today's close sits at 39% of that range, 46.8% below the 52-week high.
Oct 7, 2026 — ARCT dips 1.8% to $12.77, a 1-month low
- Closed at $12.77, -1.77% vs the prior close of $13.00. Day range $12.59–$13.40, opened at $12.71.
- Volume was 517.10K shares, 0.5x its 50-day average of 1.05M — lighter than usual.
- Price is +4.2% vs its 50-day average ($12.25) and +48.5% vs its 200-day average ($8.60).
- 52-week range $5.50–$24.17; today's close sits at 39% of that range, 47.2% below the 52-week high.
Oct 6, 2026 — ARCT slides 11.3% to $13.00, a 1-month low
- Closed at $13.00, -11.32% vs the prior close of $14.66. Day range $12.97–$15.04, opened at $14.70.
- Volume was 884.70K shares, 0.8x its 50-day average of 1.05M.
- Price is +7.4% vs its 50-day average ($12.11) and +51.7% vs its 200-day average ($8.57).
- 52-week range $5.50–$24.17; today's close sits at 40% of that range, 46.2% below the 52-week high.
Oct 5, 2026 — ARCT jumps 12.5% to $14.66
- Closed at $14.66, +12.51% vs the prior close of $13.03. Day range $12.68–$15.17, opened at $13.01.
- Volume was 1.32M shares, 1.3x its 50-day average of 1.03M.
- Price is +22.5% vs its 50-day average ($11.96) and +71.7% vs its 200-day average ($8.54).
- 52-week range $5.50–$24.17; today's close sits at 49% of that range, 39.3% below the 52-week high.
Oct 2, 2026 — ARCT dips 1.4% to $13.03, a 1-month low, 4 down days in a row
- Closed at $13.03, -1.36% vs the prior close of $13.21. Day range $12.79–$13.65, opened at $13.33.
- Volume was 744.80K shares, 0.7x its 50-day average of 1.02M.
- Price is +10.6% vs its 50-day average ($11.78) and +53.3% vs its 200-day average ($8.50).
- 52-week range $5.50–$24.17; today's close sits at 40% of that range, 46.1% below the 52-week high.
- That makes 4 straight losses.
ARCT latest news & SEC filings
Every SEC filing by or about ARCT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $2.96M (prior year $28.30M) (-89.5% vs Jun 30, 2025)
- Net income: -$23.79M (prior year -$9.18M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.84 (prior year -$0.34) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade ARCT
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 3, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.19% (largest 12.5%). That is a volatile stock.
- Liquidity: about 761.87K shares (≈$7.88M) trade per day on average.
- 52-week position: $10.34 vs a range of $5.50–$24.17 (26% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 23, 2026; 8-K Aug 25, 2026; 10-Q Aug 6, 2026.
- Share count: 28.42M shares outstanding (Aug 4, 2026), +4.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ARCT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.27 | 11.31 | 10.25 | 10.34 | 831.61K |
| Oct 15, 2026 | 11.00 | 11.42 | 10.61 | 11.27 | 492.90K |
| Oct 14, 2026 | 11.64 | 12.05 | 11.06 | 11.12 | 588.80K |
| Oct 13, 2026 | 12.42 | 12.65 | 11.86 | 12.03 | 464.10K |
| Oct 12, 2026 | 13.64 | 13.75 | 12.57 | 12.61 | 419.40K |
| Oct 9, 2026 | 13.18 | 14.32 | 12.87 | 13.74 | 675.60K |
| Oct 8, 2026 | 12.60 | 12.96 | 12.03 | 12.87 | 677.80K |
| Oct 7, 2026 | 12.71 | 13.40 | 12.59 | 12.77 | 517.10K |
| Oct 6, 2026 | 14.70 | 15.04 | 12.97 | 13.00 | 884.70K |
| Oct 5, 2026 | 13.01 | 15.17 | 12.68 | 14.66 | 1.32M |
| Oct 2, 2026 | 13.33 | 13.65 | 12.79 | 13.03 | 744.80K |
| Oct 1, 2026 | 13.49 | 13.87 | 13.18 | 13.21 | 497.30K |
| Sep 30, 2026 | 13.80 | 14.06 | 13.52 | 13.69 | 592.90K |
| Sep 29, 2026 | 14.45 | 14.47 | 13.26 | 13.70 | 435.50K |
| Sep 28, 2026 | 13.55 | 14.78 | 13.55 | 14.46 | 824.60K |
| Sep 25, 2026 | 14.34 | 14.48 | 13.30 | 13.85 | 629.50K |
| Sep 24, 2026 | 13.94 | 14.50 | 13.80 | 14.12 | 1.50M |
| Sep 23, 2026 | 14.44 | 14.61 | 13.26 | 13.30 | 1.07M |
| Sep 22, 2026 | 14.65 | 14.69 | 13.88 | 14.38 | 1.07M |
| Sep 21, 2026 | 16.37 | 16.55 | 14.60 | 14.69 | 1.00M |
About Arcturus Therapeutics
Arcturus Therapeutics (ARCT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1768224.
ARCT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James F Barlow | Director | Jun 15, 2026 |
| Peter C Farrell | Director | Jun 15, 2026 |
| Edward W Holmes | Director | Jun 15, 2026 |
| Jing L. Marantz | Director | Jun 15, 2026 |
| John Markels | Director | Jun 15, 2026 |
| Magda Marquet | Director | Jun 15, 2026 |
| Joseph E Payne | President and CEO | Dec 19, 2025 |
| Moncef Slaoui | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Pad Chivukula | Chief Scientific Officer & COO | Dec 19, 2025 |
| Lance Kurata | Chief Legal Officer | Dec 19, 2025 |
| Dennis Mulroy | Chief Financial Officer | May 7, 2026 |
| Joseph E Payne | President and CEO | Dec 19, 2025 |
| Joseph Roberts | Controller | Dec 19, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ARCT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $82.03M | $-65.78M | -2.40 | $-74.27M |
| Dec 31, 2024 | $152.31M | $-80.94M | -3.00 | $-59.75M |
| Dec 31, 2023 | $166.80M | $-29.73M | -1.12 | $-18.10M |
| Dec 31, 2022 | $206.00M | $9.35M | 0.35 | $31.99M |
| Dec 31, 2021 | $12.36M | $-203.67M | -7.74 | $-135.04M |
Latest balance sheet: total assets $224.31M, total liabilities $52.50M, cash $191.48M (as of Jun 30, 2026).
ARCT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $6.08 |
| May 7, 2026 | 8-K Item 2.02 (results) | $8.90 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $7.91 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $8.78 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $11.39 |
| May 12, 2025 | 8-K Item 2.02 (results) | $11.59 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $15.97 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $18.74 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 7, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ARCT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.